Cytarabine

Product manufactured by Hospira, Inc.

Application Nr Approved Date Route Status External Links
ANDA075383 None Intrathecal None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Indications And Usage Cytarabine Injection In Combination With Other Approved Anti-Cancer Drugs Is Indicated For Remission Induction In Acute Non-Lymphocytic Leukemia Of Adults And Pediatric Patients. It Has Also Been Found Useful In The Treatment Of Acute Lymphocytic Leukemia And The Blast Phase Of Chronic Myelocytic Leukemia. Intrathecal Administration Of Cytarabine Injection (Preservative Free Preparations Only) Is Indicated In The Prophylaxis And Treatment Of Meningeal Leukemia.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Cytarabine CYTARABINE ZINC3795098

Comments